Stockscreener 앱 받기
0.8461
1.03%
-0.0088
시장 영업 전:
.87
0.0239
+2.82%
전일 마감가:
$0.8549
열려 있는:
$0.86
하루 거래량:
59,325
Relative Volume:
0.01
시가총액:
$875.47K
수익:
-
순이익/손실:
$-6.90M
주가수익비율:
-0.0604
EPS:
-14.0152
순현금흐름:
$-6.65M
1주 성능:
-10.94%
1개월 성능:
-0.17%
6개월 성능:
-55.23%
1년 성능:
-86.17%
1일 변동 폭
$0.835
$0.8657
1주일 범위
$0.83
$0.97
52주 변동 폭
$0.8002
$16.68
Bluejay Diagnostics Inc Stock (BJDX) Company Profile
명칭
Bluejay Diagnostics Inc
전화
(978) 631-0152
주소
360 MASSACHUSETTS AVENUE, SUITE 203, ACTON
Compare BJDX vs ABT, MDT, SYK, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BJDX
Bluejay Diagnostics Inc
|
0.8461 | 953.28K | 0 | -6.90M | -6.65M | -14.02 |
ABT
Abbott Laboratories
|
96.69 | 175.27B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
86.44 | 113.38B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
272.96 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.23 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.19 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
Bluejay Diagnostics Inc 주식(BJDX)의 최신 뉴스
Bluejay Diagnostics Inc (NYSE: BJDX) Stock Price, News & Analysis - kalkine.com.au
Bluejay Diagnostics (BJDX) Slips 1.94% to $1.01 as Micro-Cap Diagnostics Stock Tests Key SupportDonchian Channel - siam.in
Monday's Gap-Up and Gap-Down Stock Movers: September 8 - ChartMill
Bluejay Diagnostics expands federal access via Lovell partnership - TipRanks
Bluejay Diagnostics Taps Lovell Government Services as Exclusive SDVOSB Distributor for U.S. Government - TradingView
Bluejay Diagnostics Federal Healthcare Partnership Builds Commercial Pathway Ahead of FDA Clearance - Yahoo Finance
Premarket Movers for Sept. 8, 2026: Notable Gainers and Losers - ChartMill
BJDX Stock Gains Momentum On Sepsis Trial, Cash Boost - timothysykes.com
BJDX Stock Draws Traders As Trial, Cash Runway And 13G Align - StocksToTrade
These stocks are moving in today's pre-market session - ChartMill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
BJDX Stock Draws Traders As Cash, Trial And 13G Align - StocksToTrade
Bluejay Diagnostics, Inc. and Lovell Government Services, Inc. Announce Partnership to Expand Access to U.S. Federal Healthcare Markets - marketscreener.com
Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets - marketscreener.com
A medical test company is preparing for about 170 VA medical centers. FDA clearance or authorization comes first. - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
NASDAQ Stocks Under $1: FNGR, DUO, EPOW, CYAB in Focus Now! - FinancialContent
BJDX Stock Draws Traders As Sepsis Test Milestones Hit - StocksToTrade
Armistice Capital Acquires 142,728 Shares of Bluejay Diagnostics Inc (BJDX) - GuruFocus
Bluejay (BJDX) Session-Level Review: Loses 4.90% to Close at $0.97 at the Close; Reference Levels: the Session Ends Within the Reported Technical Boundaries for the Current SessionGrowth ETF - vinanet.vn
Bluejay Diagnostics (BJDX) links director options to FDA nod - Stock Titan
Bluejay Diagnostics (BJDX) links director’s 100K options to FDA clearance - Stock Titan
Bluejay Diagnostics (BJDX) ties director’s options to FDA device clearance - Stock Titan
Bluejay Diagnostics (NASDAQ: BJDX) insider updates share holdings - Stock Titan
Bluejay Diagnostics (NASDAQ: BJDX) ties director options to FDA clearance - Stock Titan
Bluejay (BJDX) Session-Level Review: Loses 4.90% to Close at $0.97 at the Close; Reference Levels - careplusvn.com
Armistice Capital discloses 9.99% Bluejay Diagnostics (BJDX) position in Schedule 13G - Stock Titan
Bluejay Diagnostics (BJDX) investor group discloses 9.99% ownership with warrants - Stock Titan
Form 8K Bluejay Diagnostics Inc For: 13 August By Investing.com - Investing.com Nigeria
Bluejay Advances Symphony Platform, Strengthens Cash Position - TipRanks
Form 8K Bluejay Diagnostics Inc For: 13 August - Investing.com India
Bluejay Diagnostics Q2 Results: EPS loss narrows 80% YoY to $(1.12) - scanx.trade
Bluejay Diagnostics completes enrollment in sepsis test study - Investing.com
Bluejay Diagnostics completes enrollment in sepsis test study By Investing.com - Investing.com Australia
Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization - The Manila Times
Bluejay Diagnostics Completes Enrollment in SYMON-II Pivotal Study, Advances Toward 510(k) Submission and Commercialization - quiverquant.com
Bluejay completes 750-patient study enrollment for Symphony IL-6 - Stock Titan
Bluejay Diagnostics, Inc. Q2 2026: Net loss $(2.32M), EPS $(1.12) — 10-Q Summary - TradingView
Bluejay Diagnostics (BJDX) warns on going concern and Nasdaq listing risk - Stock Titan
BJDX Forecast & Price Target - TradingKey
Bluejay Diagnostics Inc (BJDX) Stock News Today - tradingkey.com
Why Are Traders Watching Bluejay Diagnostics (NASDAQ:BJDX) This Week? - Kalkine Media
Bullish Volume: RITR, IGC, BJDX, CISS Lead Active Sub-$1 Stocks to Watch - Barchart.com
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
BJDX Stock Dips As Pivotal Sepsis Study Finishes Early - StocksToTrade
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
BJDX Stock Dips As Pivotal Sepsis Trial Finishes Enrollment Early - StocksToTrade
Bluejay Diagnostics (NASDAQ:BJDX) soars 47% premarket; warrant financing still subject to conditions - TechStock²
Trending Stocks Today | Julong Soars 42.47% Pre-Market - Moomoo
Ready for the party🤓 - Moomoo
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Bluejay Diagnostics Inc (BJDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Bluejay Diagnostics Inc 주식 (BJDX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| HRT FINANCIAL LP | 10% Owner |
Jul 10 '26 |
Sale |
1.40 |
34,938 |
48,913 |
92,055 |
| Wurth Douglas Clark | Director |
Mar 14 '26 |
Buy |
2.00 |
12,500 |
25,000 |
12,608 |
| Dey Indranil | President and CEO |
Mar 14 '26 |
Buy |
2.00 |
12,500 |
25,000 |
12,522 |
| CHASE DONALD R | Director |
Mar 14 '26 |
Buy |
2.00 |
12,500 |
25,000 |
12,525 |
| ZEIDMAN FRED S | Director |
Mar 14 '26 |
Buy |
2.00 |
12,500 |
25,000 |
12,500 |
| Dey Svetlana | Director |
Mar 14 '26 |
Buy |
2.00 |
12,500 |
25,000 |
12,501 |
0.87%
자본화:
|
볼륨(24시간):